JP2022512332A5 - - Google Patents

Info

Publication number
JP2022512332A5
JP2022512332A5 JP2021532224A JP2021532224A JP2022512332A5 JP 2022512332 A5 JP2022512332 A5 JP 2022512332A5 JP 2021532224 A JP2021532224 A JP 2021532224A JP 2021532224 A JP2021532224 A JP 2021532224A JP 2022512332 A5 JP2022512332 A5 JP 2022512332A5
Authority
JP
Japan
Prior art keywords
piggybac transposase
seq
nucleic acid
piggybac
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512332A (ja
JP7441840B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065129 external-priority patent/WO2020123327A1/en
Publication of JP2022512332A publication Critical patent/JP2022512332A/ja
Publication of JP2022512332A5 publication Critical patent/JP2022512332A5/ja
Application granted granted Critical
Publication of JP7441840B2 publication Critical patent/JP7441840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021532224A 2018-12-10 2019-12-09 変異したpiggybacトランスポザーゼ Active JP7441840B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862777325P 2018-12-10 2018-12-10
US62/777,325 2018-12-10
US201962925516P 2019-10-24 2019-10-24
US62/925,516 2019-10-24
PCT/US2019/065129 WO2020123327A1 (en) 2018-12-10 2019-12-09 Mutated piggybac transposase

Publications (3)

Publication Number Publication Date
JP2022512332A JP2022512332A (ja) 2022-02-03
JP2022512332A5 true JP2022512332A5 (https=) 2022-11-01
JP7441840B2 JP7441840B2 (ja) 2024-03-01

Family

ID=69143664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532224A Active JP7441840B2 (ja) 2018-12-10 2019-12-09 変異したpiggybacトランスポザーゼ

Country Status (22)

Country Link
US (1) US12570966B2 (https=)
EP (1) EP3894549B1 (https=)
JP (1) JP7441840B2 (https=)
KR (1) KR20210101270A (https=)
CN (2) CN113195712B (https=)
AU (2) AU2019398101B2 (https=)
BR (1) BR112021011063A2 (https=)
CA (1) CA3121268A1 (https=)
CL (2) CL2021001488A1 (https=)
DK (1) DK3894549T3 (https=)
ES (1) ES2991895T3 (https=)
FI (1) FI3894549T3 (https=)
HU (1) HUE068630T2 (https=)
IL (1) IL283314A (https=)
LT (1) LT3894549T (https=)
MX (1) MX2021006783A (https=)
PL (1) PL3894549T3 (https=)
PT (1) PT3894549T (https=)
SG (1) SG11202106049RA (https=)
SI (1) SI3894549T1 (https=)
TW (1) TWI862531B (https=)
WO (1) WO2020123327A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122716A1 (en) * 2021-12-22 2023-06-29 Vanderbilt University Next generation transpososomes
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
KR20260013198A (ko) * 2023-05-12 2026-01-27 론자 바이올로직스 피엘씨 고수율 생성물 생산을 위한 트랜스포사제를 이용한 하이브리드 일시적 형질감염
US20250027052A1 (en) 2023-07-21 2025-01-23 Amgen Inc. Vectors incorporating a combination of promoters driving selectable marker expression
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
CN120737218B (zh) * 2025-08-15 2026-01-06 云南彤宁生物制药技术有限公司 融合蛋白、调控系统及利用该系统构建转基因细胞的方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ES2227669T3 (es) 1996-01-11 2005-04-01 Immunex Corporation Elementos de secuencia que aumentan la expresion (ease) para sistemas de expresion de eurocariotas.
US6218185B1 (en) 1996-04-19 2001-04-17 The United States Of America As Represented By The Secretary Of Agriculture Piggybac transposon-based genetic transformation system for insects
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7105343B1 (en) 2000-10-31 2006-09-12 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector Piggybac
DE60335637D1 (de) 2002-07-24 2011-02-17 Manoa Biosciences Inc Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren
US7932088B1 (en) 2005-04-25 2011-04-26 University Of Notre Dame Du Lac High efficiency transformation of Plasmodium falciparum by the lepidopteran transposon, piggyBac
WO2007100821A2 (en) 2006-02-28 2007-09-07 University Of Notre Dame Piggybac constructs in vertebrates
US20090042297A1 (en) 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
AU2010206374B2 (en) 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
WO2010085699A2 (en) 2009-01-23 2010-07-29 The Johns Hopkins University Mammalian piggybac transposon and methods of use
EP2401376A4 (en) 2009-02-25 2012-11-28 Univ Johns Hopkins TRANSPOSON PIGGYBAC VARIANTS AND METHODS OF USE
US8399643B2 (en) 2009-02-26 2013-03-19 Transposagen Biopharmaceuticals, Inc. Nucleic acids encoding hyperactive PiggyBac transposases
US20100311116A1 (en) 2009-06-04 2010-12-09 Excellgene Sa Fast generation of high expression stable cell lines expressing recombinant proteins under minimal and short-term selective pressure
ES2697535T3 (es) 2009-06-11 2019-01-24 Inter Univ Research Institute Corporation Research Organization Of Information And Systems Procedimiento para la producción de proteína
CN102762585B (zh) * 2010-02-12 2016-01-20 DPx控股有限公司 单一单元抗体纯化
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
GB201014169D0 (en) 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
WO2012074758A1 (en) 2010-11-16 2012-06-07 Transposagen Bioharmaceuticals, Inc. Hyperactive piggybac transposases
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2013012824A2 (en) 2011-07-15 2013-01-24 The Johns Hopkins University Trichoplusia ni piggybac transposases with reduced integration activity
US8846373B2 (en) 2011-07-29 2014-09-30 The University Of Wyoming Methods of using a bacterial GlcNAc-6-P 2′- epimerase to promote sialylation of glycoconjugates
SI3366775T2 (sl) 2011-11-18 2025-12-31 Alnylam Pharmaceuticals, Inc. Modificirana sredstva RNAI
FI3536797T3 (fi) 2013-02-01 2023-03-23 Selexis Sa Siirtogeenin tehostettu ilmentäminen ja prosessointi
WO2014138306A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Engager cells for immunotherapy
CN103360464A (zh) 2013-07-17 2013-10-23 武汉摩尔生物科技有限公司 多肽、编码该多肽的dna分子、载体、制备方法及应用
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
DK3129487T3 (da) 2014-04-09 2020-11-30 Dna Twopointo Inc Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
EP3018200A1 (en) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
CN105154473B (zh) 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
CA3001312A1 (en) 2015-10-08 2017-04-13 Dna2.0, Inc. Dna vectors, transposons and transposases for eukaryotic genome modification
KR102249982B1 (ko) 2015-12-14 2021-05-11 게놈프론티어 테라퓨틱스 인코포레이티드 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도
CN109312361A (zh) 2016-02-26 2019-02-05 波赛伊达治疗学股份有限公司 转座子系统及应用方法
EP3219800A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
US20230183884A1 (en) 2016-11-30 2023-06-15 China Agricultural University A method for crispr library screening
WO2019046815A1 (en) 2017-08-31 2019-03-07 Poseida Therapeutics, Inc. TRANSPOSON SYSTEM AND METHODS OF USE
WO2020123410A1 (en) 2018-12-10 2020-06-18 Amgen Inc. CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2022512332A5 (https=)
JP2005120106A5 (https=)
JP2012095652A5 (https=)
JP2015096070A5 (https=)
FI3872085T3 (fi) Esimuotoiset virussekvenssit ja niiden käytöt
JP2017513479A5 (https=)
EA201890220A1 (ru) Вакцина против rsv
RU2019144161A (ru) Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
JP2022062113A5 (https=)
JP2016104045A5 (https=)
EP3597760A3 (en) Adeno-associated virus vector
WO2012145509A3 (en) Adeno-associated-virus rep sequences, vectors, and viruses
JOP20220043A1 (ar) بروتين كابسيد vp1 معدل معزول من aav5
JP2018531624A5 (https=)
JP2009501530A5 (https=)
RU2017102986A (ru) Новые люциферазы и способы их использования
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
RU2015148190A (ru) Слитые полипептиды и вакцины
JP2017529840A5 (https=)
JP2019526270A5 (https=)
JP2015536347A5 (https=)
JP2010183921A5 (https=)
JP2016512251A5 (https=)
JP2017530718A5 (https=)
JP2013502217A5 (https=)